![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/06/26/2904464/0/en/EyePoint-Pharmaceuticals-to-Highlight-DURAVYU-vorolanib-intravitreal-insert-Clinical-and-Regulatory-Progress-and-Pipeline-Innovation-at-R-D-Day-2024.html
https://www.prnewswire.com/news-releases/eyepoint-pharmaceuticals-announces-updated-positive-interim-safety-and-efficacy-data-from-ongoing-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd-301481159.html
https://pipelinereview.com/index.php/2021111479688/Small-Molecules/EyePoint-Pharmaceuticals-Reports-Positive-Interim-Safety-and-Efficacy-Data-from-Phase-1-DAVIO-Clinical-Trial-Evaluating-EYP-1901-for-the-Treatment-of-Wet-AMD.html